57O Efficacy, safety and tolerability of MEDI4736 (durvalumab [D]), a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib (G): A phase I expansion in TKI-naïve patients (pts) with EGFR mutant NSCLC

Journal of Thoracic Oncology

Volumn 11, Issue 4, 2016, Pages S79-

  Gibbons, D L ^a   Chow, L Q ^b   Kim, D W ^c   Kim, S W ^d   Yeh, T ^e   Song, X ^f   Jiang, H ^e   Taylor, R ^e   Karakunnel, J ^f   Creelan, B ^g  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c Seoul National University Hospital   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e ASTRAZENECA   (United Kingdom)

^f MEDIMMUNE   (United States)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DURVALUMAB; GEFITINIB;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; EGFR GENE; FEMALE; GENE MUTATION; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOGENICITY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NON SMALL CELL LUNG CANCER; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RASH; RECEPTOR GENE;

EID: 85043626285     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1016/S1556-0864(16)30171-X     Document Type: Article

References (0)